Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29845324 | 0.95 | REN (0.46) | RENSLC6A2NTSR2NTSR1 | |
| SCHEMBL30385689 | 0.94 | REN (0.47) | RENSLC6A2NTSR2NTSR1CTSD | |
| SCHEMBL29630596 | 0.92 | MEN1 (0.43) | RENCAPN1CTSB | |
| SCHEMBL30997440 | 0.91 | REN (0.45) | RENSLC6A2CAPN1CTSBANPEP | |
| SCHEMBL30997442 | 0.91 | REN (0.45) | RENSLC6A2CAPN1CTSBANPEP | |
| SCHEMBL31072130 | 0.89 | REN (0.46) | RENNTSR2NTSR1 | |
| SCHEMBL29591934 | 0.87 | GRB2 (0.43) | SLC6A2 | |
| SCHEMBL29590547 | 0.87 | OPRK1 (0.46) | RENSLC6A2CTSD | |
| SCHEMBL11092435 | 0.87 | REN (0.47) | RENSLC6A2NTSR2NTSR1 | |
| SCHEMBL29630560 | 0.87 | OPRK1 (0.46) | RENSLC6A2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | REN 1530/4885SLC6A2 2983/4885CAPN1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.